亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

医学 无容量 吉西他滨 顺铂 危险系数 尿路上皮癌 转移性尿路上皮癌 肿瘤科 泌尿科 内科学 无进展生存期 胃肠病学 免疫疗法 置信区间 化疗 膀胱癌 癌症
作者
Michiel S. van der Heijden,Guru Sonpavde,Thomas Powles,Andrea Necchi,Mauricio Burotto,Michael Schenker,Juan Pablo Sade,Aristotelis Bamias,Philippe Beuzeboc,Jens Bedke,Jan Oldenburg,Gurkamal S. Chatta,Yüksel Ürün,Dingwei Ye,Zhisong He,Begoña P. Valderrama,Ja Hyeon Ku,Yoshihiko Tomita,Jeiry Filian,Lily Wang,Daniela Purcea,Mona Patel,Federico Nasroulah,Matthew D. Galsky
出处
期刊:The New England Journal of Medicine [New England Journal of Medicine]
卷期号:389 (19): 1778-1789 被引量:47
标识
DOI:10.1056/nejmoa2309863
摘要

No new agent has improved overall survival in patients with unresectable or metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy.In this phase 3, multinational, open-label trial, we randomly assigned patients with previously untreated unresectable or metastatic urothelial carcinoma either to receive intravenous nivolumab (at a dose of 360 mg) plus gemcitabine-cisplatin (nivolumab combination) every 3 weeks for up to six cycles, followed by nivolumab (at a dose of 480 mg) every 4 weeks for a maximum of 2 years, or to receive gemcitabine-cisplatin alone every 3 weeks for up to six cycles. The primary outcomes were overall and progression-free survival. The objective response and safety were exploratory outcomes.A total of 608 patients underwent randomization (304 to each group). At a median follow-up of 33.6 months, overall survival was longer with nivolumab-combination therapy than with gemcitabine-cisplatin alone (hazard ratio for death, 0.78; 95% confidence interval [CI], 0.63 to 0.96; P = 0.02); the median survival was 21.7 months (95% CI, 18.6 to 26.4) as compared with 18.9 months (95% CI, 14.7 to 22.4), respectively. Progression-free survival was also longer with nivolumab-combination therapy than with gemcitabine-cisplatin alone (hazard ratio for progression or death, 0.72; 95% CI, 0.59 to 0.88; P = 0.001). The median progression-free survival was 7.9 months and 7.6 months, respectively. At 12 months, progression-free survival was 34.2% and 21.8%, respectively. The overall objective response was 57.6% (complete response, 21.7%) with nivolumab-combination therapy and 43.1% (complete response, 11.8%) with gemcitabine-cisplatin alone. The median duration of complete response was 37.1 months with nivolumab-combination therapy and 13.2 months with gemcitabine-cisplatin alone. Grade 3 or higher adverse events occurred in 61.8% and 51.7% of the patients, respectively.Combination therapy with nivolumab plus gemcitabine-cisplatin resulted in significantly better outcomes in patients with previously untreated advanced urothelial carcinoma than gemcitabine-cisplatin alone. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 901 ClinicalTrials.gov number, NCT03036098.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顺其自然完成签到 ,获得积分10
1分钟前
1分钟前
waters发布了新的文献求助10
1分钟前
知行合一完成签到 ,获得积分10
2分钟前
2分钟前
微笑紫真发布了新的文献求助10
2分钟前
waters完成签到,获得积分20
2分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
小燕子完成签到 ,获得积分10
4分钟前
eason完成签到,获得积分10
4分钟前
4分钟前
4分钟前
隐形曼青应助依然灬聆听采纳,获得10
4分钟前
lxyonline完成签到 ,获得积分10
5分钟前
6分钟前
lxyonline发布了新的文献求助10
6分钟前
yishan发布了新的文献求助10
6分钟前
6分钟前
江三村完成签到 ,获得积分10
6分钟前
7分钟前
245完成签到,获得积分10
7分钟前
245发布了新的文献求助10
7分钟前
传奇完成签到 ,获得积分10
8分钟前
领导范儿应助微笑紫真采纳,获得10
9分钟前
今后应助善良山灵采纳,获得10
9分钟前
刻苦的芜完成签到 ,获得积分10
10分钟前
yishan完成签到,获得积分10
10分钟前
陈无敌完成签到 ,获得积分10
10分钟前
10分钟前
善良山灵发布了新的文献求助10
10分钟前
科研小白鼠完成签到 ,获得积分10
11分钟前
善良山灵完成签到,获得积分10
11分钟前
woxinyouyou完成签到,获得积分0
14分钟前
1461完成签到 ,获得积分10
14分钟前
20分钟前
微笑紫真发布了新的文献求助10
20分钟前
20分钟前
温哒哒发布了新的文献求助10
20分钟前
桐桐应助温哒哒采纳,获得10
20分钟前
微笑紫真完成签到,获得积分10
20分钟前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
巫和雄 -《毛泽东选集》英译研究 (2013) 800
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The three stars each: the Astrolabes and related texts 500
Revolutions 400
Diffusion in Solids: Key Topics in Materials Science and Engineering 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2451066
求助须知:如何正确求助?哪些是违规求助? 2124465
关于积分的说明 5405784
捐赠科研通 1853256
什么是DOI,文献DOI怎么找? 921688
版权声明 562263
科研通“疑难数据库(出版商)”最低求助积分说明 493029